Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 63, Issue 2, 2008, Pages 127-134

  Wang, Wei ^a   Le, Wei Dong ^a   Pan, Tianhong ^a   Stringer, Janet L ^a   Jaiswal, Anil K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

NRH:quinone oxidoreductase 2; Parkinson's disease; Promoter polymorphism

Indexed keywords

DOPAMINE; GENOMIC DNA; REACTIVE OXYGEN METABOLITE; NRH - QUINONE OXIDOREDUCTASE2; NRH QUINONE OXIDOREDUCTASE2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SP3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DETERMINATION; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; N RIBOSYLDIHYDRONICOTINAMIDE QUINONE OXIDOREDUCTASE 2 GENE; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SKIN FIBROBLAST; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALLELES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); QUINONE REDUCTASES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 42449128395     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/63.2.127     Document Type: Article

References (34)

1. Fahn S, Przedborski S. Parkinsonism. In: Rowland LP, ed. Merritt's Neurology. New York: Lippincott Williams & Wilkins; 2000:679-693.
2. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. In: Yahr M, Bergmann KJ, eds. Parkinson's Disease. New York: Raven Press; 1987:19-34.
3. Pakkenberg B, Moller A, Gundersen HJG, Mouritzen A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54:30-33.
4. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem. 1985;45:1951-1953.
5. Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex 1) deficiency in Parkinson's disease. J Neurochem. 1990;55:2142-2145.
6. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of 1-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol. 1993;243:241-247.
7. Sian J, Gerlach M, Youdim MBH, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm. 1999;106:443-476.
8. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol. 1998;44(Suppl):S72-S84.
9. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992;32:804-812.
10. Smythies J, Galzigna L. The oxidative metabolism of catecholamines in the brain: a review. Biochim Biophys Acta 1998;1380:159-162.
11. D'Ischia M, Prota G. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. 1997;10:370-376.
12. Drukarch B, van Muiswinkel FL. Drug treatment of Parkinson's disease: time for phase II. Biochem Pharmacol. 2000;59:1023-1031.
13. Celli CM, Tran N, Knox R, Jaiswal AK. NRH:Quinone Oxidoreductase2 (NQO2) catalyzes metabolic activation of quinones and antitumor drugs. Biochem Pharmacol. 2006;72:366-376.
14. nd, Jaiswal AK. NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact. 2000;129:99-112.
15. Wu K, Knox R, Sun XZ, et al. Catalytic properties of NAD(P)H: quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys. 1997;347:221-228.
16. Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H: quinone reductase (DT-diaphorase). Proc Natl Acad Sci U S A. 1997;94:1669-1674.
17. Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275:31311-31317.
18. Nosjean O, Nicolas J, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol. 2001;61:1369-1379.
19. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun. 2001;288:887-892.
20. Wang W, Jaiswal AK. Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter. Free Radic Biol Med. 2004;37:1231-1243.
21. Dhakshinamoorthy S, Jaiswal AK. Small Maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:quinone oxidoreductase1 gene. J Biol Chem. 2000;275:40134-40141.
22. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometry studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol. 1983;130:1910-1917.
23. Samms WC, Perera RP, Wimalasena DS, Wimalasena K. Perturbation of dopamine metabolism by 3-amino-2-(4′-halophenyl)propenes leads to increased oxidative stress and apoptotic SH-SY5Y cell death. Mol Pharmacol. 2007;72:744-752.
24. Antolin I, Mayo JC, Sainz RM, et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res. 2002;943:163-173.
25. Buryanovskyy L, Fu Y, Boyd M, et al. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004;43:11417-11426.
26. Frankel D, Schipper HM. Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury. Exp Neurol. 1999;160:376-385.
27. Gelinas S, Martinoli MG. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res. 2002;70:90-96.
28. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect. 2003;16:299-307.
29. Iacovitti L, Stull ND, Johnston K. Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res. 1997;768:317-326.
30. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218-220.
31. 2-induced lipid peroxidation in rat brain homogenates is greatly reduced by melatonin. Neurosci Lett. 1995;195:203-205.
32. Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res. 2004;36:25-32.
33. Wang Z, Hsieh T, Zhang Z, Ma Y, Wu JM. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004;323:743-749.
34. Mailliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 2004;578:116-120.